Skip to content FinTerveys is a scientific P4-medicine -based research project that aims to produce new information concerning the utilization of genome and metabolomic information in healthcare.

Study participants´ genome-, metabolic and health information are analysed to identify individuals at risk of getting sick. An essential part of the study is to explore the effect of returning genetic risk data back to the study participants together with guidance on those actions individual can take to sustain or improve his or her health in the future. The effect of obtaining actionable health information on life style changes and health monitoring will be analysed together with healthcare professionals. Medaffcon met with Markus Perola, MD, PhD, Principal Investigator at the National Institute for Health and Welfare (THL) and Project Leader of the research project, to hear more about the goals of the study and visions how information on genome, metabolome and health can be used to promote individuals’ health.

Read below the central points of the research project:

For the project, invitation to participate has been sent to 6500 persons. These individuals were selected based on their earlier participation to the FinTerveys 2017 project led also by the National Institute of Health and Welfare. In addition, all these individuals have provided a biobank consent.

In the research project, participants will receive information of their risk for three illnesses; type II diabetes, cardiovascular disease and tendency for venous thromboembolia. These three illnesses were selected due to existing evidence on specific genetic factors that play a role in these diseases and, importantly, actionable information can be provided to those individuals who have been identified to have an increased risk for the disease. During the study, predefined information on the participants overall risk collected in the FinTerveys – research project will be utilized and the study participants will be followed for the selected medical endpoints like myocardial infarction, outbreak of type II diabetes and venous or pulmonary thrombosis.

“One of the key goals of the project is to analyse how people respond to the returned genetic risk information: are they willing to receive the information, how they will manage the information and whether knowing own risk factors will lead to lifestyle changes”, explaines Markus Perola.  

For providing back the health and risk information, “OmaP5” or OwnP5 accounts will be set up for all study participants. Besides obtaining traditional and genetic risk information separately, combined risk information based on genetic, metabolomic and life style information will be provided.

A set of questionnaires will be used to monitor life style changes after participants have received risk information. This will be done first few months after returning risk information and subsequently once a year for an overall period of five years. Each participant will also receive a “Doctor´s note”, where participants´ genetic and metabolomic risk information is described for healthcare professionals. Clinical expert groups involved in the project will provide treatment suggestions, which are reflected also to “Käypä Hoito”. Although treating physicians retain their full autonomy in making treatment decisions, Doctors´ note provides a tool to interpret the generated genetic and metabolomic risk information.

While the research project is currently under a recruitment phase, there are already plans to apply the concept to a larger group of participants. In the planned “” project, ~ 100 000 participants will be offered to receive their personal risk information. project is therefore a crucial step towards such larger studies and provides valuable insights on the general aspects regarding entering P4-medicine into healthcare practices.


Previous section:
Medaffcon's services

Next section: